STAT1 and neoplasm: According to recent studies, silvestrol, an inhibitor of the helicase activity of eukaryotic initiation factor 4A, prevents translation of the Stat1 mRNA [39] (Fig. 3G) and might therefore represent a potential therapeutic option to avoid tumor immune escape via the STAT1-PD-L1 axis.